NCT02320474View on ClinicalTrials.gov

Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

PHASE4CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

November 25, 2014

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Type 3 Choroidal Neovascularization
Interventions
DRUG

Aflibercept

Trial Locations (2)

86000

Poitiers University Hospital, Poitiers

Polyclinic of POITIERS, Poitiers

All Listed Sponsors
lead

Poitiers University Hospital

OTHER

NCT02320474 - Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3) | Biotech Hunter | Biotech Hunter